Coronary disease & ACS

Elevated Carbohydrate Antigen 125 (CA125) is Associated with Incident Heart Failure and Mortality in Acute Coronary Syndrome

ESC Heart FailPublished Prospective cohort study

Authors' conclusion

We report independent associations between elevated CA125, LV dysfunction, cardiac remodelling, incident HF and mortality post-ACS.

Study context

Population
Acute coronary syndrome (ACS) patients (73% males, mean age 67 ± 12 years)elderly subgroup n = 115
Participants
524 patients
Exposure
Higher vs lower CA125
Outcome
Incident heart failure (HF) and mortality
Follow-up
Median 27.3 months for incident HF and 39.5 months for mortality

Main finding

As reported in the abstract

Hazard ratio (95% CI)P value
Baseline CA125 (per 1-SD increase)incident HF; adjusted for age, sex, CV risk factors, renal function, revascularization
1.46(1.10–1.93)
P = 0.009
Baseline CA125 (per 1-SD)mortality; adjusted for age and sex
1.37(1.09–1.71)
P = 0.006
6-week CA125 (per increasing tertile)mortality; adjusted for age and sex; elderly subgroup
1.98(1.06–3.67)
P = 0.031
6-week CA125 (per increasing tertile)mortality; fully adjusted model; elderly subgroup
2.23(1.15–4.35)
P = 0.018

Each row per its own increment, as printed

Observational data: associations, not effects.

Further findings

OutcomeOR (95% CI)P value
LVEF deterioration (>5% absolute decrease if LVEF ≥ 50% at discharge), elderly subgroup · 1 year post-ACS3.31 (1.15–9.54)P = 0.027

Correlation of baseline CA125 with cardiac remodelling, elderly subgroup · 1 year post-ACS

Left ventricular (LV) end-diastolic volume index, Spearman's r
0.329, P < 0.001
LV end-systolic volume index, r
0.391, P < 0.001
Left atrial volume index, r
0.320, P < 0.001

Original publication

Elevated Carbohydrate Antigen 125 (CA125) is Associated with Incident Heart Failure and Mortality in Acute Coronary Syndrome. ESC Heart Fail. Published 1 September 2024. doi:10.1002/ehf2.15037

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.